Key result
Thrombolytic therapy is linked to ~50% lower mortality in stable massive PE with RV enlargement.
Why the study?
Previous studies did not determine whether the short-term benefits of thrombolysis over heparin in pulmonary embolism affect patient prognosis and justify bleeding risks.
Does thrombolytic therapy reduce mortality in patients with submassive and massive pulmonary embolism compared to heparin alone?
Does thrombolytic therapy reduce mortality in patients with submassive and massive pulmonary embolism compared to heparin alone?
Thrombolytic therapy may reduce mortality in clinically stable pulmonary embolism patients with right ventricular dysfunction, but prospective randomized trials are needed to confirm this benefit against the bleeding risks.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in stable massive PE with RV enlargement; leaves open confirmation of mortality benefit in randomized trials.
Thrombolytic agents have been consistently demonstrated to dissolve pulmonary thrombi much more rapidly and effectively than heparin alone. Rapid resolution of pulmonary embolism (PE) is accompanied by a significant decrease in pulmonary artery pressure and an improvement in right ventricular function. However, it is no longer than 7 days until the findings of patients treated with heparin improve to a similar extent. Previous studies were not designed to determine whether this short-lasting difference in favor of thrombolysis can indeed affect the prognosis of patients with PE and thus justify the 1% (or even higher) risk of cerebral or fatal bleeding. Recently, two large registries demonstrated the importance of right ventricular dysfunction assessed by echocardiography as an independent predictor of mortality. Thrombolytic treatment was shown in one of these registries to be associated with a 50% reduction of death risk in clinically stable patients with right ventricular enlargement. It was thus possible to identify a group of patients with massive PE who are most likely to benefit from early thrombolysis. These findings now have to be confirmed by a prospective randomized trial which will compare thrombolysis with heparin alone in this high-risk patient population, focusing on clinical end points such as overall and event-free survival in the acute phase of PE.
No takes yet. Share an insight, caveat, or question.
A 1999 study conducted a review in Submassive and Massive Pulmonary Embolism. Thrombolytic therapy vs. Heparin alone was evaluated. Thrombolytic therapy was associated with a 50% reduction in death risk among clinically stable patients with massive pulmonary embolism and right ventricular enlargement in registry data.
Synapse has enriched 10 related papers. Consider them for comparative context: